Dianthus Therapeutics: Funded, Clinical Momentum, and a Clear Binary Upside
Dianthus (DNTH) is a clinical-stage monoclonal antibody company riding positive Phase 3 momentum for claseprubart and an expanding autoimmune pipeline. The stock trades near $93 with a market cap around $5.1B; recent financing and institutional interest reduce near-term liquidity risk while leaving a clear binary readthrough from ongoing trials. Th…